VERACYTE, INC.
VCYT
49 insider filings · Latest: Sep 21, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | Jun 4 8:31 PM | John Leite | Proposed Sale | 13,975 | $48.69 | $680.4K | — | View → |
| Jun 4, 2026 | Jun 4 8:31 PM | MARC STAPLEY | Proposed Sale | 138,051 | $48.69 | $6.7M | — | View → |
| Jun 4, 2026 | Jun 4 8:30 PM | REBECCA CHAMBERS | Proposed Sale | 3,561 | $48.69 | $173.4K | — | View → |
| May 22, 2026 | May 27 8:19 PM | Jonathan WygantVP, Chief Accounting Officer | Sale | 24,000 | $45.40 | $1.1M | 45,434(D) | View → |
| May 20, 2026 | May 22 8:39 PM | Robert S EpsteinDirector | Sale | 10,000 | $44.01 | $440.1K | 52,446(D) | View → |
| May 20, 2026 | May 20 8:38 PM | ROBERT EPSTEIN | Proposed Sale | 10,000 | $41.69 | $416.9K | — | View → |
| May 6, 2026 | May 8 8:25 PM | Annie McguireSVP, General Counsel | Sale | 10,204 | $39.03 | $398.2K | 143,708(D) | View → |
| May 6, 2026 | May 6 8:25 PM | ANN MCGUIRE | Proposed Sale | 10,204 | $32.97 | $336.4K | — | View → |
| Mar 4, 2026 | Mar 6 9:33 PM | Rebecca ChambersChief Financial Officer | Sale | 18,341 | $36.14 | $662.9K | 131,196(D) | View → |
| Mar 4, 2026 | Mar 6 9:32 PM | Marc StapleyDirector, Chief Executive Officer | Sale | 45,523 | $35.97 | $1.6M | 357,554(D) | View → |
| Mar 4, 2026 | Mar 6 9:32 PM | John LeiteChief Commercial Officer-CLIA | Sale | 5,260 | $35.19 | $185.1K | 107,580(D) | View → |
| Mar 4, 2026 | Mar 6 9:32 PM | Annie McguireSVP, General Counsel | Sale | 6,658 | $35.55 | $236.7K | 94,706(D) | View → |
| Mar 4, 2026 | Mar 4 9:42 PM | ANN MCGUIRE | Proposed Sale | 6,658 | $35.08 | $233.6K | — | View → |
| Mar 4, 2026 | Mar 4 9:41 PM | John Leite | Proposed Sale | 5,260 | $35.08 | $184.5K | — | View → |
| Mar 4, 2026 | Mar 4 9:40 PM | REBECCA CHAMBERS | Proposed Sale | 18,341 | $35.08 | $643.4K | — | View → |
| Mar 4, 2026 | Mar 4 9:37 PM | MARC STAPLEY | Proposed Sale | 45,523 | $35.08 | $1.6M | — | View → |
| Mar 2, 2026 | Mar 4 9:16 PM | Phillip G. FebboChief Scientific & Med Officer | Sale | 13,425 | $36.16 | $485.4K | 117,346(D) | View → |
| Mar 2, 2026 | Mar 2 9:38 PM | PHILLIP FEBBO | Proposed Sale | 13,425 | $36.59 | $491.2K | — | View → |
| Dec 16, 2025 | Dec 16 9:30 PM | ANN MCGUIRE | Proposed Sale | 10,739 | $43.53 | $467.5K | — | View → |
| Dec 5, 2025 | Dec 5 9:26 PM | KARIN EASTHAM | Proposed Sale | 20,000 | $47.41 | $948.2K | — | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | Jun 5 1:38 AM | Marc StapleyDirector, Chief Executive Officer | Option Exercise | 138,051 | $36.60 | 0(D) | View → |
| May 22, 2026 | May 27 8:19 PM | Jonathan WygantVP, Chief Accounting Officer | Option Exercise | 24,000 | $24.80 | 0(D) | View → |